CAMBRIDGE, Mass., Dec. 4 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPUR) announces the acceptance of four abstracts for presentation
at the American Society for Clinical Pharmacology and Therapeutics annual
meeting to be held April 2-5, 2008. The Society is the largest scientific
and professional organization serving the discipline of clinical
pharmacology.
These abstracts address the basis for adverse event outcomes and other
key findings in previous surgical studies of Hemopure. Biopure and the
collaborating scientists also address the safety and efficacy of both
Hemopure and Hemoglobin-based oxygen carriers (HBOCs) in general. The
titles, authors and affiliations are as follows:
RISK OF ADVERSE OUTCOME DUE TO ACUTE ANEMIA IN THE ORTHOPEDIC SURGICAL
SETTING. L. B. Pearce, A. N. Pitman; Biopure Corporation, Cambridge, MA.
BREAKING THE RULES: MISINTERPRETATION OF DOSE-RESPONSE RELATIONSHIPS IN
CLINICAL TRIALS. L. B. Pearce, A. N. Pitman, A. G. Greenburg; Biopure
Corporation, Cambridge, MA.
A FLEXIBLE OUTCOME SCORING SYSTEM FOR CLINICAL TRIALS. A. N. Pitman, L.
B. Pearce; Biopure Corporation, Cambridge, MA.
APPLICATION OF A UNIQUE SCORING SYSTEM FOR NUMERICAL DETERMINATION OF A
BENEFIT RISK RATIO IN CLINICAL TRIALS. L. B. Pearce(1), A. Pitman,(1) A. G.
Greenburg,(1) D. A. Freilich,(2) L. Kaplan(3); (1)Biopure Corporation,
Cambridge, MA, (2)Naval Medical Research Center, Silver Spring, MD, (3)Yale
University School of Medicine, New Haven, CT.
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals,
called oxygen therapeutics, that are intravenously administered to deliver
oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250
(bovine)], or HBOC-201, is approved for sale in South Africa for the
treatment of surgical patients who are acutely anemic. Biopure has applied
in the United Kingdom for regulatory approval of a proposed orthopedic
surgical anemia indication. The company is developing Hemopure for several
other indications and is supporting the U.S. Navy's government-funded
efforts to develop a potential out-of-hospital trauma indication. Biopure's
veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or
HBOC-301, the only oxygen therapeutic approved by both the U.S. Food and
Drug Administration and the European Commission, is indicated for the
treatment of anemia in dogs. Biopure has sold approximately 186,000 units
of Oxyglobin.
Contact: Tiana Gorham Herb Lanzet (Investors)
Biopure Corporation H.L. Lanzet Inc.
(617) 234-6826 (212) 888-4570
IR@biopure.com lanzet@aol.com
SOURCE Biopure Corporation
 back to top
Related links:
http://www.biopure.com
http://www.prnewswire.com/comp/131224.html/
CONTACT:
Tiana Gorham, Biopure Corporation,
+1-617-234-6826, IR@biopure.com, or Herb Lanzet (Investors), H.L.
Lanzet Inc., +1-212-888-4570, lanzet@aol.com
|
